The Changing Face of cN0M0 Prostate Cancer Being Found With pN+ After Surgery in the Contemporary Era: Results of an International European Survey on Disease Management
Matteo Antonio Sacco(Azienda Ospedaliero Universitaria San Giovanni Battista), Giancarlo Marra(Royal Free London NHS Foundation Trust), Georges Fournier, Claudia Kesch(Essen University Hospital), Giorgio Gandaglia(Vita-Salute San Raffaele University), Juan Gómez Rivas(Medico), Christian D. Fankhauser(University of Zurich), Paolo Gontero(Fondazione Ricerca Molinette), Alberto Martini(The University of Texas MD Anderson Cancer Center), Felix Preißer(Royal Free London NHS Foundation Trust), Constance Thibault(Hôpital Européen Georges-Pompidou), Ignacio Puche‐Sanz(Instituto de Investigación Biosanitaria de Granada), Veeru Kasivisvanathan(University College London Hospitals NHS Foundation Trust), Massimo Valério(University Hospital of Geneva), Peter Ka‐Fung Chiu(Chinese University of Hong Kong), Kirsti Aas(University of Oslo), Martina Maggi(Policlinico Umberto I), Roderick C.N. van den Bergh(Erasmus MC), Jonathan Olivier(Université de Lille), Timo Soeterik(St. Antonius Ziekenhuis), Marco Moschini(Vita-Salute San Raffaele University), Francesco Ceci(University of Turin), Fabio Zattoni, Guillaume Ploussard(Yves Rocher (France)), Isabel Heiddeger(Innsbruck Medical University), Paweł Rajwa(University College London), Alberto Bossi(Institut Gustave Roussy), Silke Gillessen(Institute of Oncology Research)
Cited by 3
Related Papers
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656